sai-parenterals-ltd

Founded in 2001 and headquartered in Hyderabad, Sai Parenteral's is a diversified pharmaceutical formulations company. It has established a strong presence in both branded generics and the Contract Development and Manufacturing Organisation (CDMO) space.

Business Verticals

• Branded Formulations: Development and supply of generic medicines across therapeutic areas like Cardiovascular, Anti-diabetic, Neuropsychiatry, and Antibiotics.

• CDMO Services: Providing end-to-end research and manufacturing services for global and domestic pharma partners.

• Specialized Injectables: High-barrier manufacturing of sterile liquids, lyophilized (freeze-dried) powders, and pre-filled syringes.

• Dosage Diversity: Beyond injectables, the company produces tablets, capsules, liquid orals, and ointments.

Track Record

• Consistent Growth: Revenue from operations grew from ₹153.76 Cr (FY24) to ₹163.11 Cr (FY25).

• Profitability: Net profit (PAT) saw a sharp rise of 71.8%, reaching ₹14.45 Cr in FY25 compared to ₹8.41 Cr in the previous year.

• Manufacturing Hub: Operates five facilities—four in Hyderabad and one in Ongole—with key accreditations including WHO-GMP and TGA Australia.

• Global Expansion: Recently acquired a majority stake in Noumed Pharmaceuticals (Australia) to expand its footprint in regulated international markets.

Sai Parenteral's Ltd IPO GMP

As of March 20, 2026, the Grey Market Premium (GMP) is ₹0.

Note: The GMP is currently flat, reflecting a cautious market sentiment as the bidding dates approach. Premiums for pharmaceutical companies often react to the Anchor Investor interest, which is scheduled for March 23.

Sai Parenteral's Ltd IPO Allotment Status

The allotment is scheduled to be finalized on Mar 30, 2026.

Check Sai Parenteral's Allotment Status To check your status online, visit: [Check Allotment Status Here]

You can verify your status via:

• Registrar's website (Bigshare Services Pvt Ltd)

• NSE/BSE official portals

• Using your PAN number or Application ID

Strengths

• High Entry Barriers: Sterile injectable manufacturing requires complex infrastructure and stringent regulatory compliance, creating a natural moat.

• Diversified Portfolio: Presence across multiple high-growth therapeutic segments reduces dependence on any single drug category.

• Integrated R&D: In-house research capabilities facilitate faster product dossiers (500+ existing dossiers) and new product launches.

• Strategic Acquisitions: The Australian acquisition provides a direct gateway to high-margin regulated markets.

Weakness

• Product Concentration: A significant portion of revenue (~44%) is derived from the injectable segment; any regulatory or demand shift here could impact financials.

• Geographic Concentration: Most manufacturing assets are located in Telangana and Andhra Pradesh, making them susceptible to regional disruptions.

• High Working Capital: The pharma business involves high inventory levels and long credit periods, putting pressure on cash flows.

• Intense Competition: Faces aggressive pricing competition from both large-cap Indian pharma giants and global generic manufacturers.

How the Company Will Use IPO Money

The fresh issue proceeds (₹285 Cr) will be utilized for:

• Capacity Expansion: ₹110.80 crores for upgrading and expanding existing manufacturing units.

• New R&D Centre: ₹18.02 crores to establish a state-of-the-art research facility.

• Strategic Investment: ₹35.64 crores for the acquisition of Noumed Pharmaceuticals (Australia) through its Singapore subsidiary.

• Debt & Working Capital: ₹14.30 crores for debt repayment and ₹33.00 crores for incremental working capital needs.

Lead Manager & Registrar

• Lead Manager: Arihant Capital Markets Limited.

• Registrar: Bigshare Services Pvt Ltd Phone: +91 22 6263 8200 Email: ipo@bigshareonline.com